Blog

Jon Rowland-Beer and his partner decided to ditch the traditional dinner last year, replacing it with a charcuterie board.

“We’re not the biggest fans of roast dinners anyway. I hate gravy and my partner doesn’t like vegetables,” said Jon, from Cardiff.

Taking the price and food waste into account, they opted for a vast selection of cheese, meat and dips.

“We can sit down, have a nibble, and then just go back and forth and graze,” said the 30-year-old.

Their charcuterie board this year will feature elements of a typical Christmas dinner, but with a twist.

“I’m going to make pigs in blankets but wrap them in salami instead of bacon, and we’ll add a couple of Yorkshire puddings,” he said.

Jon’s friends think what they do is “funny but great”, but not everyone is a fan of the charcuterie board.

“My mum thinks I’m mad. She’s a great cook and I’ve always felt a little guilty. It breaks her heart,” he added.

New York – December 24, 2025 – Cooley advised Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B), a shingles vaccine candidate and a differentiated clinical-stage pipeline, on its definitive agreement to be acquired by Sanofi for $15.50 per share in cash, representing an equity value of $2.2 billion. The acquisition strengthens Sanofi’s position in adult immunization by bringing together Dynavax’s adult hepatitis B vaccine and promising shingles asset with Sanofi’s global scale, development capabilities and commercial reach.

Lawyers Bill Roegge, Barbara Borden, Steve Przesmicki, Barbara Mirza, Austin Holt, David Burns and Jane Adams led the Cooley team advising Dynavax.

Cooley previously advised Dynavax on its successful proxy contest in June 2025, its $225 million convertible notes offering in March 2025 and its $100 million accelerated share repurchase program in November 2024.